Suppr超能文献

多药耐药的非P-糖蛋白药物外排机制

Non-P-glycoprotein drug export mechanisms of multidrug resistance.

作者信息

List A F

机构信息

University of Arizona Cancer Center, Bone Marrow Transplant Program, Tucson 85724-5024, USA.

出版信息

Semin Hematol. 1997 Oct;34(4 Suppl 5):20-4.

PMID:9408957
Abstract

A variety of cellular mechanisms of multidrug resistance (MDR) have been identified in human drug-resistant cell lines, and may play an important role in the clinical response of hematologic malignancies to chemotherapy. P-glycoprotein (P-gp)-mediated drug efflux is the most well-characterized cellular mechanism of MDR; however, several other non-P-gp membrane transporter proteins have also been implicated in the development of an MDR phenotype in hematologic malignancies. These include the MDR-related protein (MRP), the lung-resistance protein (LRP), and the transporter of antigenic peptides (TAP). The transporter proteins MRP and TAP are both members of the adenosine triphosphate (ATP)-binding cassette (ABC) family of transmembrane transporters, but each has distinct differences in substrate specificity. Despite effective modulation of P-gp, one or more of these alternate mechanisms of drug resistance may contribute to an MDR phenotype in tumor cell lines. Development of multifunctional MDR modulators or novel therapeutics may be necessary to effectively circumvent MDR in hematologic malignancies.

摘要

在人类耐药细胞系中已发现多种细胞性多药耐药(MDR)机制,这些机制可能在血液系统恶性肿瘤对化疗的临床反应中起重要作用。P-糖蛋白(P-gp)介导的药物外排是最具特征的细胞性MDR机制;然而,其他几种非P-gp膜转运蛋白也与血液系统恶性肿瘤MDR表型的发生有关。这些蛋白包括多药耐药相关蛋白(MRP)、肺耐药蛋白(LRP)和抗原肽转运体(TAP)。转运蛋白MRP和TAP均为三磷酸腺苷(ATP)结合盒(ABC)家族跨膜转运体的成员,但它们在底物特异性方面存在明显差异。尽管对P-gp有有效的调节作用,但这些耐药的替代机制中的一种或多种可能导致肿瘤细胞系出现MDR表型。开发多功能MDR调节剂或新型治疗方法可能是有效克服血液系统恶性肿瘤MDR所必需的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验